Study of Fremanezumab in Patients With Interstitial Cystitis-Bladder Pain Syndrome

Study Title

A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome

Teva Identifier

TV48125-CNS-20022

ClinicalTrials.gov Identifier

NCT04447729

Study Status

Withdrawn

Trial Condition(s)

Interstitial Cystitis

Interventions

Drug: fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
pain icon for clinical trials

Key Participation Requirements

Gender

Female

Age Range

18 Years and older

Trial Duration

October 15, 2020 - February 10, 2022

Phase

Phase 2

Study Type

Interventional